This report provides an in-depth analysis of business ethics, corporate social responsibility (CSR), and sustainability within the pharmaceutical sector, using GlaxoSmithKline (GSK) as a primary case study. The introduction establishes the context of business ethics and its relevance to the pharmaceutical industry, highlighting key issues of sustainable resource use and ethical behavior. The main body delves into critical discussions of CSR and sustainability challenges faced by pharmaceutical companies, including climate change, transparency demands, corporate culture conflicts, and the integration of CSR into the value chain. It also examines sustainability challenges such as desertification, soil exploitation, loss of biodiversity, high energy consumption, and diverse supply chains. The report critically analyzes ethical and moral issues within GSK, referencing the ethical challenges related to high research and development costs and pricing strategies. The report provides recommendations for improving business practices in the pharmaceutical sector, which includes revising regulations, improving manufacturing standards, upgrading operational management, and monitoring legal and regulatory developments to ensure ethical and sustainable practices. The report concludes with a summary of key findings and recommendations to promote responsible business practices in the pharmaceutical industry.
![[object Object]](/_next/static/media/star-bottom.7253800d.svg)
